Table 2.

IL-6, sIL-6Rα, and sgp130 in the culture supernatants of PMN and PBMC from control and patients with Lyme disease.

	Control n = 30		Patients n = 43
	PMN	PBMC	PMN	PBMC
	$\overline{x}$ ± SD	$\overline{x}$ ± SD	$\overline{x}$ ± SD	$\overline{x}$ ± SD
IL-6 (pg/mL)
Unstimulated cells	8 ± 3.3	24 ± 4.7 b	19 ± 8.3*	39 ± 14 b *
LPS-stimulated	16 ± 3.8 a	39 ± 9.0 a b	21 ± 6.5	43 ± 13 b
rhIL-15 stimulated	11 ± 2.7 a	29 ± 6.1 b	26 ± 9.3 a *	42 ± 12 b *
sIL-6Rα (ng/mL)
Unstimulated cells	2.3 ± 0.9	4 ± 1.4 b	1.6 ± 0.9	3 ± 0.9 b
LPS-stimulated	3.9 ± 1.0 a	5.4 ± 2.1	2.2 ± 0.8 a *	3.5 ± 0.9 b *
rhIL-15 stimulated	3 ± 0.8	5.2 ± 1.9 b	2 ± 0.5 a	3.4 ± 0.6 a b *
sgp130 (ng/mL)
Unstimulated cells	29 ± 9.2	31 ± 6.4	28 ± 6.7	27 ± 8.4*
LPS-stimulated	42 ± 10 a	44 ± 12 a	37 ± 10 a	37 ± 12 a
rhIL-15 stimulated	33 ± 8.7	36 ± 6.7	30 ± 8.2	33 ± 7.3*

*Statistical differences between control and patients groups (P < .001).

^aStatistical differences between unstimulated cells and cells incubated with LPS or rhIL-15 (P < .001).

^bStatistical differences between PMN and PBMC (P < .001).